BR112016012229A2 - métodos de produção de polipeptídeos - Google Patents

métodos de produção de polipeptídeos

Info

Publication number
BR112016012229A2
BR112016012229A2 BR112016012229A BR112016012229A BR112016012229A2 BR 112016012229 A2 BR112016012229 A2 BR 112016012229A2 BR 112016012229 A BR112016012229 A BR 112016012229A BR 112016012229 A BR112016012229 A BR 112016012229A BR 112016012229 A2 BR112016012229 A2 BR 112016012229A2
Authority
BR
Brazil
Prior art keywords
fusion polypeptide
fusion
polypeptide
pro
production methods
Prior art date
Application number
BR112016012229A
Other languages
English (en)
Inventor
Kopetzki Erhard
Niewoehner Jens
Maier Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016012229A2 publication Critical patent/BR112016012229A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

é relatado no presente um método de produção de polipeptídeos de fusão que compreende as etapas de (a) cultivo de células de mamíferos que compreendem um ácido nucleico que codifica um polipeptídeo de fusão variante em que a sequência de aminoácidos do polipeptídeo de fusão foi modificado por meio da substituição, em um pró-polipeptídeo de fusão, do local de divisão de protease endógeno entre o pró-peptídeo e o polipeptídeo de fusão com um local de divisão de protease artificial ou exógeno (com relação às origens das partes do polipeptídeo de fusão); e (b) recuperação do polipeptídeo de fusão ou pró-polipeptídeo de fusão da célula ou do meio de cultivo, de forma a produzir o polipeptídeo de fusão (recombinante).
BR112016012229A 2013-12-20 2014-12-10 métodos de produção de polipeptídeos BR112016012229A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198738 2013-12-20
PCT/EP2014/077196 WO2015091144A1 (en) 2013-12-20 2014-12-10 Improved recombinant polypeptide production methods

Publications (1)

Publication Number Publication Date
BR112016012229A2 true BR112016012229A2 (pt) 2017-09-26

Family

ID=49886715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012229A BR112016012229A2 (pt) 2013-12-20 2014-12-10 métodos de produção de polipeptídeos

Country Status (11)

Country Link
US (2) US10370692B2 (pt)
EP (1) EP3083977B1 (pt)
JP (1) JP6618912B2 (pt)
KR (1) KR20160098277A (pt)
CN (1) CN105829542A (pt)
BR (1) BR112016012229A2 (pt)
CA (1) CA2929149A1 (pt)
HK (1) HK1223980A1 (pt)
MX (1) MX368656B (pt)
RU (2) RU2019134445A (pt)
WO (1) WO2015091144A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220304T1 (hr) 2015-06-24 2022-05-13 F. Hoffmann - La Roche Ag Anti-transferinska receptorska protutijela s prilagođenim afinitetom
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2018375796A1 (en) 2017-11-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
TWI801664B (zh) * 2018-09-21 2023-05-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
KR102027955B1 (ko) 2019-01-24 2019-10-02 이현종 로스터 후드용 내부커버 및 이의 제조방법
KR20220145877A (ko) * 2020-02-25 2022-10-31 모멘타 파머슈티컬스 인코포레이티드 글리칸의 시알화를 위한 효소
IT202000032423A1 (it) * 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita
US20230340058A1 (en) * 2021-11-11 2023-10-26 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010819A1 (en) 1991-11-26 1993-06-10 Alkermes, Inc. Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
PL200586B1 (pl) 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
IL129427A0 (en) * 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
SE9901428D0 (sv) 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
CA2412882A1 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0412186D0 (en) * 2004-05-28 2004-06-30 Univ Cambridge Tech Production of recombinant protein
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
CA2656558A1 (en) 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
AU2007291501B2 (en) * 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
CA2716738A1 (en) * 2008-04-07 2009-10-15 Zymogenetics, Inc. Thrombin activator compositions and methods of making and using the same
WO2010011695A1 (en) 2008-07-21 2010-01-28 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
MX2011010158A (es) 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
KR102099462B1 (ko) 2010-11-30 2020-04-10 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
WO2012087835A2 (en) 2010-12-22 2012-06-28 Boston Biomedical Research Institute Compositions and methods for enhancing protein folding
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
CA2828662A1 (en) 2011-04-20 2012-10-26 Roche Glycart Ag Method and constructs for the ph dependent passage of the blood-brain-barrier
US20150044718A1 (en) * 2012-02-29 2015-02-12 Hoffmann-La Roche Inc. On-column enzymatic cleavage
EP2668901A1 (en) 2012-05-31 2013-12-04 Roche Diagniostics GmbH Sensor insertion assembly, sensor cartridge, and inserter
RS58928B1 (sr) 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru

Also Published As

Publication number Publication date
MX368656B (es) 2019-10-10
KR20160098277A (ko) 2016-08-18
JP2017500040A (ja) 2017-01-05
EP3083977B1 (en) 2018-02-28
MX2016007207A (es) 2016-07-21
RU2019134445A (ru) 2019-12-20
RU2711322C1 (ru) 2020-01-16
US11098338B2 (en) 2021-08-24
CA2929149A1 (en) 2015-06-25
EP3083977A1 (en) 2016-10-26
US20190271021A1 (en) 2019-09-05
US10370692B2 (en) 2019-08-06
US20160326562A1 (en) 2016-11-10
HK1223980A1 (zh) 2017-08-11
CN105829542A (zh) 2016-08-03
WO2015091144A1 (en) 2015-06-25
JP6618912B2 (ja) 2019-12-11
RU2016128367A (ru) 2018-01-25

Similar Documents

Publication Publication Date Title
BR112016012229A2 (pt) métodos de produção de polipeptídeos
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
BR112018004377A2 (pt) cepas de levedura para a expressão e secreção de proteínas heterólogas em temperaturas elevadas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX2019008417A (es) Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas.
EA201791275A1 (ru) Способы получения ctp-модифицированных полипептидов длительного действия
BR112018003214A2 (pt) fabricação de fosfatases alcalinas
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
MX2016008249A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
EA202091349A1 (ru) Способы культивирования клеток
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
EA201791059A1 (ru) Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
BRPI1006628B8 (pt) método para produzir uma enzima lipolítica
AR095117A1 (es) TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO
PE20211303A1 (es) Polipeptidos del factor vii de accion corta
BR112017018030A2 (pt) variante de celobiohidrolase, polinucleotídeo isolado, célula hospedeira recombinante, método para produção de uma variante de celobiohidrolase, composição de enzima inteiro ou composição de cultura de células, e, processos para degradação de um material celulósico, para produção de um produto de fermentação e para fermentação de um material celulósico
WO2015015516A3 (en) Expression vector for production of recombinant proteins in prokaryotic host cells
EA028913B9 (ru) Получение антител высокой чистоты в pichia pastoris
MY184625A (en) Methods of producing long acting ctp-modified growth hormone polypeptides

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]